<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>the akampioneer</title>
	<atom:link href="http://akampioneer.com/feed" rel="self" type="application/rss+xml" />
	<link>http://akampioneer.com</link>
	<description></description>
	<lastBuildDate>Mon, 14 May 2012 08:00:40 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.1.1</generator>
		<item>
		<title>Company News: Curetis AG Achieves CE-Marking for Unyvero™ Solution and Initiates Commercialization</title>
		<link>http://akampioneer.com/company-news/company-news-curetis-ag-achieves-ce-marking-for-unyvero%e2%84%a2-solution-and-initiates-commercialization.html</link>
		<comments>http://akampioneer.com/company-news/company-news-curetis-ag-achieves-ce-marking-for-unyvero%e2%84%a2-solution-and-initiates-commercialization.html#comments</comments>
		<pubDate>Mon, 14 May 2012 08:00:40 +0000</pubDate>
		<dc:creator>akampion</dc:creator>
				<category><![CDATA[Company News]]></category>
		<category><![CDATA[CE-marking]]></category>
		<category><![CDATA[commercialization]]></category>
		<category><![CDATA[Curetis AG]]></category>
		<category><![CDATA[ECCMID]]></category>
		<category><![CDATA[in-vitro]]></category>
		<category><![CDATA[infectious diseases]]></category>
		<category><![CDATA[molecular diagnostics]]></category>
		<category><![CDATA[pneumonia diagnostics]]></category>
		<category><![CDATA[Unyvero™]]></category>
		<category><![CDATA[Unyvero™ P50 Pneumonia Cartridge]]></category>

		<guid isPermaLink="false">http://akampioneer.com/?p=2717</guid>
		<description><![CDATA[- Successful completion of performance evaluation study; CE Mark for Unyvero™ instrument system and pneumonia application - Curetis AG, an innovative molecular diagnostics company focusing on the development and commercialization of in-vitro diagnostic products for infectious diseases, today announced that the company has achieved the CE marking for its Unyvero™ suite of instruments and the [...]]]></description>
		<wfw:commentRss>http://akampioneer.com/company-news/company-news-curetis-ag-achieves-ce-marking-for-unyvero%e2%84%a2-solution-and-initiates-commercialization.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Innovation Radar: Probiodrug&#8217;s Nature Paper Receives Broad Coverage</title>
		<link>http://akampioneer.com/innovation-radar/innovation-radar-probiodrugs-nature-paper-receives-broad-coverage.html</link>
		<comments>http://akampioneer.com/innovation-radar/innovation-radar-probiodrugs-nature-paper-receives-broad-coverage.html#comments</comments>
		<pubDate>Fri, 04 May 2012 08:09:12 +0000</pubDate>
		<dc:creator>akampion</dc:creator>
				<category><![CDATA[Innovation Radar]]></category>
		<category><![CDATA[Abeta peptide]]></category>
		<category><![CDATA[Alzheimer's disease]]></category>
		<category><![CDATA[Barack Obama]]></category>
		<category><![CDATA[Hans-Ulrich Demuth]]></category>
		<category><![CDATA[Harvard Medical School]]></category>
		<category><![CDATA[pGlu-Abeta]]></category>
		<category><![CDATA[prions]]></category>
		<category><![CDATA[Probiodrug]]></category>
		<category><![CDATA[Rudy Tanzi]]></category>
		<category><![CDATA[Science News]]></category>
		<category><![CDATA[tau protein]]></category>

		<guid isPermaLink="false">http://akampioneer.com/?p=2709</guid>
		<description><![CDATA[This week&#8217;s Nature publication by researchers of Probiodrug AG and the University of Virginia has received broad coverage in the international media. In Germany and Austria, it made major news in TV (ARD, MDR, ORF) and radio stations (dlf, MDR, dradio), while in the US Rudy Tanzi, neurogeneticist of Harvard Medical School and an advisor on the [...]]]></description>
		<wfw:commentRss>http://akampioneer.com/innovation-radar/innovation-radar-probiodrugs-nature-paper-receives-broad-coverage.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Company News: Jean-Paul Prieels joins VAXIMM’s Board of Directors</title>
		<link>http://akampioneer.com/company-news/company-news-jean-paul-prieels-joins-vaximm%e2%80%99s-board-of-directors.html</link>
		<comments>http://akampioneer.com/company-news/company-news-jean-paul-prieels-joins-vaximm%e2%80%99s-board-of-directors.html#comments</comments>
		<pubDate>Thu, 03 May 2012 08:11:52 +0000</pubDate>
		<dc:creator>akampion</dc:creator>
				<category><![CDATA[Company News]]></category>
		<category><![CDATA[Basel]]></category>
		<category><![CDATA[BB Biotech Ventures]]></category>
		<category><![CDATA[BioMedPartners]]></category>
		<category><![CDATA[cancer vaccines]]></category>
		<category><![CDATA[GlaxoSmithKline]]></category>
		<category><![CDATA[Jean-Paul Prieels]]></category>
		<category><![CDATA[joint venture]]></category>
		<category><![CDATA[Mannheim]]></category>
		<category><![CDATA[Merck KGaA]]></category>
		<category><![CDATA[Merck Serono Ventures]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[pancreatic cancer]]></category>
		<category><![CDATA[spin-off]]></category>
		<category><![CDATA[Sunstone Capital]]></category>
		<category><![CDATA[VAXIMM AG]]></category>
		<category><![CDATA[VXM01]]></category>

		<guid isPermaLink="false">http://akampioneer.com/?p=2698</guid>
		<description><![CDATA[VAXIMM AG, a Swiss-German biotech spin-off from Merck KGaA focusing on cancer vaccines, announced today the appointment of Jean-Paul Prieels as a new member of its Board of Directors. Dr. Prieels is a renowned industry expert in the vaccine field. He held various executive positions at GlaxoSmithKline, where he headed the vaccine research and development [...]]]></description>
		<wfw:commentRss>http://akampioneer.com/company-news/company-news-jean-paul-prieels-joins-vaximm%e2%80%99s-board-of-directors.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Company News: Nanobiotix and Thomas Jefferson University Start Research Collaboration</title>
		<link>http://akampioneer.com/company-news/company-news-nanobiotix-and-thomas-jefferson-university-start-research-collaboration.html</link>
		<comments>http://akampioneer.com/company-news/company-news-nanobiotix-and-thomas-jefferson-university-start-research-collaboration.html#comments</comments>
		<pubDate>Wed, 02 May 2012 15:55:33 +0000</pubDate>
		<dc:creator>akampion</dc:creator>
				<category><![CDATA[Company News]]></category>
		<category><![CDATA[2-year preclinical research program]]></category>
		<category><![CDATA[Bo Lu]]></category>
		<category><![CDATA[collaboration]]></category>
		<category><![CDATA[Laurent Levy]]></category>
		<category><![CDATA[Nanobiotix]]></category>
		<category><![CDATA[NanoXray]]></category>
		<category><![CDATA[NBTXR3]]></category>
		<category><![CDATA[Thomas Jefferson University]]></category>

		<guid isPermaLink="false">http://akampioneer.com/?p=2690</guid>
		<description><![CDATA[- Nanomedicine and Medical Education leaders are joining their forces in the United States to accelerate the development of NanoXray - Nanobiotix, a company developing novel cancer nanotherapeutics and Thomas Jefferson University, one of Philadelphia&#8217;s premier medical and health sciences universities, today announced that they have entered into a research collaboration to accelerate the development [...]]]></description>
		<wfw:commentRss>http://akampioneer.com/company-news/company-news-nanobiotix-and-thomas-jefferson-university-start-research-collaboration.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Company News: Probiodrug AG, Collaborators Explain Interplay of Key Suspects in Alzheimer’s Disease</title>
		<link>http://akampioneer.com/company-news/company-news-probiodrug-ag-collaborators-explain-interplay-of-key-suspects-in-alzheimer%e2%80%99s-disease.html</link>
		<comments>http://akampioneer.com/company-news/company-news-probiodrug-ag-collaborators-explain-interplay-of-key-suspects-in-alzheimer%e2%80%99s-disease.html#comments</comments>
		<pubDate>Wed, 02 May 2012 00:00:20 +0000</pubDate>
		<dc:creator>akampion</dc:creator>
				<category><![CDATA[Company News]]></category>
		<category><![CDATA[Abeta peptide]]></category>
		<category><![CDATA[Alzheimer's disease]]></category>
		<category><![CDATA[Hans-Ulrich Demuth]]></category>
		<category><![CDATA[Journal of Neurochemistry]]></category>
		<category><![CDATA[Konrad Glund]]></category>
		<category><![CDATA[LMO]]></category>
		<category><![CDATA[Nature]]></category>
		<category><![CDATA[pGlu-Abeta]]></category>
		<category><![CDATA[prion diseases]]></category>
		<category><![CDATA[prions]]></category>
		<category><![CDATA[Probiodrug]]></category>
		<category><![CDATA[tau protein]]></category>
		<category><![CDATA[University of Virginia]]></category>

		<guid isPermaLink="false">http://akampioneer.com/?p=2684</guid>
		<description><![CDATA[Nature paper demonstrates that toxicity in AD is induced by pyroglutamate Abeta and is tau protein dependent Pyroglutamate Ab (“pyroglu Ab”) a predominant, highly toxic fraction of Aβ found in the brains of Alzheimer’s disease patients, triggers the formation of toxic oligomers exhibiting prion-like behavior and initiating neurotoxicity via a tau protein-dependent pathway, thereby explaining [...]]]></description>
		<wfw:commentRss>http://akampioneer.com/company-news/company-news-probiodrug-ag-collaborators-explain-interplay-of-key-suspects-in-alzheimer%e2%80%99s-disease.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

